---
document_datetime: 2025-11-26 15:49:37
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/qarziba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: qarziba-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.7485998
conversion_datetime: 2025-12-22 21:28:48.192708
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Qarziba

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|------------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA_IN / | C.I HUMAN AND VETERINARY MEDICINAL | 26/11/2025                          |                                             | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000312776                     | PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                                                                                                                                                                                                                    |            |     |                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type II /                   | B.I.e) Design Space and post-approval change management protocols - B.I.e.2 Introduction of a post approval change management protocol related to the active substance - Accepted                                                                                                                                                                                                                                                                                                                                          | 06/11/2025 | N/A | EMA/VR/0000282166 |
| Variation type II / EMA/VR/0000302377 | This was an application for a group of variations. B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.f Change outside the approved specifications limits range for the active substance - Accepted | 06/11/2025 | N/A |                   |

<div style=\"page-break-after: always\"></div>

| Variation type IB /                   | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted                                                                                                                                                                   | 17/10/2025   | N/A   | EMA/VR/0000302850   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|---------------------|
| Variation type IB / EMA/VR/0000301302 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted | 17/10/2025   | N/A   |                     |

<div style=\"page-break-after: always\"></div>

|                                            | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                                                                                                                                               |            |     |                 |                                                                                                   |
|--------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|---------------------------------------------------------------------------------------------------|
| Annual reassessment - H / EMA/S/0000282178 | - Annual Reassessment -                                                                                                                                                                                                                                                                                                                                                                                                     | 16/10/2025 | N/A |                 |                                                                                                   |
| Variation type IB / EMA/VR/0000281134      | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted | 10/07/2025 | N/A |                 |                                                                                                   |
| Variation type IA / EMA/VR/0000263543      | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                           | 07/04/2025 |     | Annex II and PL |                                                                                                   |
| PSUR / EMA/PSUR/0000248495                 | - -                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                 | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the risk-benefit |

<div style=\"page-break-after: always\"></div>

| balance of medicinal products containing dinutuximab beta remains unchanged and therefore recommends the maintenance of the marketing authorisation(s).   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|